Domain-Specific Efficacy of Accelerated Repetitive Transcranial Magnetic Stimulation in Neuropsychiatric Disorders: A Systematic Review and Meta-Analysis.

Biol PsychiatryDec 1, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Hangbin Zhang, Jacob Green, Shraddha Dwivedi et al.

✦ AI-curated · Sources linked

In 30 seconds

This preregistered systematic review and random-effects meta-analysis assessed accelerated repetitive transcranial magnetic stimulation (arTMS; at least two sessions daily) versus sham in randomized trials across psychiatric symptom domains. The review included 44 trials with 1,671 participants. Compared with sham, arTMS showed a moderate effect on depressive symptoms (Hedges’ g = 0.61; 95% CI, 0.38 to 0.85), with improvements also reported in anxiety, obsessive-compulsive symptoms, working memory, and declarative memory. Stimulation parameters and participant characteristics moderated outcomes in some domains; reported adverse events were mild and transient.

Key findings

  • For depressive symptoms, arTMS versus sham had Hedges’ g = 0.61 (95% CI, 0.38 to 0.85).
  • Improvements versus sham were reported for anxiety (g = 0.43; 95% CI, 0.05 to 0.81) and obsessive-compulsive symptoms (g = 0.45; 95% CI, 0.02 to 0.88).
  • Working memory improved (g = 0.45; 95% CI, 0.11 to 0.79), as did declarative memory (g = 0.30; 95% CI, 0.02 to 0.58).
  • Session frequency, intersession interval, cumulative pulse dose, age, and sex moderated outcomes in specific domains; adverse events were mild and transient.

Why it matters

The findings suggest that arTMS may affect several symptom and cognitive domains, rather than a single diagnostic category, and that outcomes may vary with stimulation parameters and participant characteristics. This supports evaluating domain-specific outcomes and treatment moderators in future trials. The reported mild, transient adverse events are relevant when considering the intervention’s safety profile, while the evidence remains based on comparisons with sham in randomized trials.

What to keep in mind

The review reports outcomes across 20 symptom domains, with moderator effects specific to some domains; the abstract does not provide details on follow-up duration or the certainty of evidence for individual outcomes.

Source

Published in Biol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.